Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Ecnoglutide on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Ecnoglutide is a once-weekly injection for type 2 diabetes and for long-term weight management. It was discovered and developed in China by Hangzhou Sciwind Biosciences, and in China it is sold as 先维盈® in a prefilled pen, with Pfizer China handling its commercial launch there.
China's National Medical Products Administration (NMPA) approved it in two steps:
It is a prescription endocrinology medicine and should be started and monitored by a diabetologist or endocrinologist.
After a meal, the gut releases a hormone called GLP-1. It helps the pancreas release insulin when blood sugar is high, slows down how fast the stomach empties and makes you feel full sooner. Ecnoglutide is a long-acting copy of this hormone. What makes it different is that it is "cAMP-biased": it switches on the main signalling route inside the cell while largely avoiding a second route (β-arrestin) that makes the receptor shut down over time. The company describes it as the first approved medicine of this biased type anywhere in the world.
Weight management (SLIMMER): this phase 3 trial, published in The Lancet Diabetes & Endocrinology in 2025, enrolled 664 Chinese adults with obesity or overweight who did not have diabetes. After 40 weeks, average body weight fell by 9.1%, 10.9% and 13.2% on the 1.2 mg, 1.8 mg and 2.4 mg doses, compared with no change (+0.1%) on placebo. Between 77% and 87% of people on the medicine lost at least 5% of their weight, against 16% on placebo. By week 48, the company reports a 15.4% average loss on the 2.4 mg dose (15.1% more than placebo).
Type 2 diabetes (EECOH-1): in 211 adults whose sugar was not controlled by diet and exercise alone or with a single oral tablet, HbA1c dropped by 1.96% on 0.6 mg and 2.43% on 1.2 mg after 24 weeks, compared with 0.87% on placebo. 80.3% of people on the 1.2 mg dose reached an HbA1c below 7%.
Type 2 diabetes with metformin (EECOH-2): in 621 adults already taking metformin, both doses lowered HbA1c by about 1.9% at 32 weeks and were at least as good as an established once-weekly comparison medicine (1.65%).
It is injected under the skin once a week. The pen sold in China holds 2.0 mg per mL in a 1.2 mL cartridge and lets the dose be adjusted from the starting dose up to the maintenance dose. In the trials, the dose was raised slowly to reduce stomach upset:
The exact schedule on the Chinese label should be followed, and your doctor will decide which dose is right for you.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Stomach and appetite effects: as with other medicines that act on the GLP-1 hormone, the most common side effects are digestive and mostly mild to moderate. In the EECOH-1 diabetes trial, reduced appetite affected 21.7% to 26.8% of people on the medicine (4.2% on placebo), diarrhoea 11.3% to 24.6% (5.6% on placebo) and nausea 7.2% to 12.7% (9.9% on placebo). These effects were most frequent while the dose was being increased and eased over time.
Overall: in the SLIMMER weight trial, 93% of people on the medicine and 84% on placebo reported at least one side effect, mostly digestive, and only 10 of the 499 people treated with it stopped because of side effects. Safety in pregnancy, breastfeeding and children has not been established in the published trials, so tell your doctor if you are pregnant, planning a pregnancy or breastfeeding. Read the full Chinese prescribing information with your doctor before starting.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The injection can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. You can also browse other imported medicines in our endocrinology section.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The prefilled pens are kept and shipped exactly as directed on the Chinese pack, using temperature-controlled shipping. Because the dose is increased step by step over the first few months, we plan quantities with your doctor so there is no gap in treatment. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating clinic on a valid prescription.
Diabetes and obesity clinics in Delhi see patients from across North India, and our New Delhi dispatch point keeps delivery times short.
Endocrinologists in Mumbai can request the pens for a named patient and receive a written quote before anything is ordered.
Patients in Bangalore can have each supply delivered to their home or clinic once the prescription has been checked.
A major centre for diabetes care in South India, where doctors can share HbA1c and weight records with us to start the import.
We time each delivery around the dose steps your doctor has planned, so the next strength is ready when it is needed.
Shipments to Kolkata and the eastern states are packed to keep the pens within the storage range printed on the pack.
Patients in Pune can use the same documented import route, with updates at every stage.
Doctors in Ahmedabad can send us the prescription and recent reports to begin the import.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the patient or the treating clinic.
Patients across Rajasthan can receive the medicine without travelling, as long as the import is in their own name.
We coordinate delivery to patients and clinics across Uttar Pradesh on a valid prescription.
Patients in Kochi and nearby Kerala cities can have the pens delivered to their home or clinic.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
.webp)
